论文部分内容阅读
目的 探讨肺耐药蛋白 (lrp)基因和多药耐药相关蛋白 (mrp)基因表达与初治急性白血病 (AL)患者化疗效果的关系。方法 用逆转录聚合酶链反应方法检测 5 8例初治AL患者骨髓单个核细胞中lrp和mrp的mRNA表达。结果 初治急性淋巴细胞白血病 (ALL)患者lrp和mrp阳性表达率分别为 15 0 %和 4 0 0 % ,初治急性非淋巴细胞白血病 (ANLL)患者lrp和mrp阳性表达率分别为15 8%和 4 2 1% ;在ALL和ANLL组 ,lrp和mrp基因阳性与阴性患者的首次完全缓解 (CR)经统计学分析 ,差异无显著性 (P >0 0 5 ) ;而lrp和mrp基因双阳性与双阴性患者的首次CR经统计学分析 ,差异有显著性 (P <0 0 5 ) ;lrp和mrp基因两者无相关性。结论 lrp和mrp单独作为预测初治AL患者化疗效果的敏感性较差 ,而两者联合检测则是预示原发耐药的良好指标
Objective To investigate the relationship between lung cancer resistance protein (lrp) gene and multidrug resistance-related protein (mrp) gene expression and chemotherapy in patients with newly diagnosed acute leukemia (AL). Methods Reverse transcription polymerase chain reaction (RT-PCR) was used to detect the mRNA expression of lrp and mrp in the bone marrow mononuclear cells of 58 untreated AL patients. Results The positive rates of lrp and mrp in newly diagnosed acute lymphoblastic leukemia (ALL) were 150% and 400% respectively. The positive rates of lrp and mrp in newly diagnosed acute non-lymphocytic leukemia (ANLL) were 15.8% And 42.1% respectively. There was no significant difference in the first complete remission (CR) between ALL and ANLL patients between positive and negative patients with lrp and mrp genes (P> 0.05) There was a significant difference between the first CR of sex and double-negative patients (P <0.05). There was no correlation between lrp and mrp genes. Conclusions lrp and mrp alone are less sensitive to predict the effect of chemotherapy in newly diagnosed AL patients. However, the combined detection of lrp and mrp is a good predictor of primary drug resistance